| Abstrakt: |
Keywords: Adrenal Cortical Steroids; Biotechnology; Dermatological Agents; Drug Delivery; Drug Delivery Systems; Drugs and Therapies; Emerging Technologies; Eye Diseases and Conditions; Glucocorticoids; Health and Medicine; Hormones; Inhaled Corticosteroids; Nanodrugs; Nanopharmaceuticals; Nanotechnology; Nasal Steroids; Ophthalmic Antiinflammatory Agents; Ophthalmic Preparations; Pharmaceuticals; Respiratory Agents; Respiratory Inhalant Products; Retinal Diseases and Conditions; Topical Steroids; Triamcinolone Therapy EN Adrenal Cortical Steroids Biotechnology Dermatological Agents Drug Delivery Drug Delivery Systems Drugs and Therapies Emerging Technologies Eye Diseases and Conditions Glucocorticoids Health and Medicine Hormones Inhaled Corticosteroids Nanodrugs Nanopharmaceuticals Nanotechnology Nasal Steroids Ophthalmic Antiinflammatory Agents Ophthalmic Preparations Pharmaceuticals Respiratory Agents Respiratory Inhalant Products Retinal Diseases and Conditions Topical Steroids Triamcinolone Therapy 1762 1762 1 07/24/23 20230724 NES 230724 2023 JUL 28 (NewsRx) -- By a News Reporter-Staff News Editor at Gene Therapy Weekly -- Current study results on retinal diseases and conditions have been published. Different posterior segment diseases including age-related macular degeneration, diabetic macular edema, retinal vein occlusions, uveitis, and cystoid macular edema, among others, have been historically treated with intravitreal corticosteroids injections, and more recently with intravitreal corticosteroids drug implants. [Extracted from the article] |
